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Urokinase plasminogen activator (uPA) is an extracellular matrix-degrading protease involved in cancer invasion
and metastasis, interacting with plasminogen activator inhibitor-1 (PAI-1), which was originally identified as a
blood-derived endogenous fast-acting inhibitor of uPA. At concentrations found in tumor tissue, however, both
PAI-1 and uPA promote tumor progression and metastasis. Consistent with the causative role of uPA and PAI-1 in
cancer dissemination, several retrospective and prospective studies have shown that elevated levels of uPA and
PAI-1 in breast tumor tissue are statistically independent and potent predictors of poor patient outcome, including
adverse outcome in the subset of breast cancer patients with lymph node-negative disease. In addition to being
prognostic, high levels of uPA and PAI-1 have been shown to predict benefit from adjuvant chemotherapy in
patients with early breast cancer. The unique clinical utility of uPA/PAI-1 as prognostic biomarkers in lymph
node-negative breast cancer has been confirmed in two independent level-of-evidence-1 studies (that is, in a
randomized prospective clinical trial in which the biomarker evaluation was the primary purpose of the trial and in
a pooled analysis of individual data from retrospective and prospective studies). Thus, uPA and PAI-1 are among
the best validated prognostic biomarkers currently available for lymph node-negative breast cancer, their main
utility being the identification of lymph node-negative patients who have HER-2-negative tumors and who can
be safely spared the toxicity and costs of adjuvant chemotherapy. Recently, a phase II clinical trial using the
low-molecular-weight uPA inhibitor WX-671 reported activity in metastatic breast cancer.Introduction
The ideal cancer biomarker should possess all or most
of the following properties [1,2]:
 have an analytically validated assay for its
measurement,
 have undergone validation for addressing a specific
clinical problem,
 have been shown to have clinical utility such as
improving patient outcome, enhancing quality of
life, or reducing cost of care,
 have a cost-effective assay, and
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criteria are the estrogen receptor (ER) [3] and the oncopro-
tein HER-2 (human epidermal growth factor receptor 2)
[4]. Though not that widely used in the clinic at present,
two other biomarkers - the serine protease urokinase plas-
minogen activator (uPA) and its inhibitor PAI-1 (plasmino-
gen activator inhibitor-1) - also meet most of the above
criteria. Indeed, uPA and PAI-1 are among the best vali-
dated biomarkers currently available for breast cancer,
having undergone clinical validation and been shown to
have clinical utility in two independent level-of-evidence-1
(LOE-1) studies [5,6]. These LOE-1 studies involved valid-
ation in both a multicenter randomized prospective clin-
ical trial in which validation of the biomarkers was the
primary aim of the trial and a pooled analysis of individu-
alized data from both unpublished and published studies
[7-9]. Promising data from animal models suggest that
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aims of this article are to provide an updated overview on
uPA and PAI-1 as prognostic or predictive biomarkers in
breast cancer (or both) and to discuss the potential thera-
peutic value of uPA in breast cancer.
Biology of urokinase plasminogen activator and
plasminogen activator inhibitor-1
Though referred to as a kinase, uPA does not possess
any kinase activity. Rather, uPA is a protease, belonging
to the serine peptidase family S1 of Clan PA, MEROPS
identification S01.231, located on chromosome 10q24
[13,14]. Unlike most serine proteases and indeed most
mammalian proteases, uPA has two notable characteris-
tics. Firstly, in contrast to many proteases, uPA appears
to have a restricted substrate specificity, its only identified
biological substrate being the proenzyme plasminogen,
which it converts to the enzymatically active serine prote-
ase plasmin. However, in vitro evidence suggests that uPA
can cleave proteins other than plasminogen, such as fibro-
nectin, alpha6 integrin, hepatocyte growth factor (HGF),
urokinase plasminogen activator receptor (uPAR), and
uPA itself [10,13,15]. In contrast to uPA, plasmin is a
broad-spectrum protease, with the potential to cleave
multiple substrates. In particular, it can degrade or re-
model several extracellular matrix (ECM) components
such as laminin, fibronectin, tenascin C, and osteopontin
[16,17]. By cleaving ECM proteins, plasmin can release
and thus activate growth factors sequestered at this site.
Growth factors shown to be released from the ECM by
plasmin include fibroblast growth factor 2, transforming
growth factor-beta, and HGF [16]. These released and ac-
tivated growth factors, following binding to their cognate
receptors, can result in increased proliferation, migration,
invasion, and metastasis.
In addition to its ability to cleave ECM substrates,
plasmin can activate the zymogen forms of specific matrix
metalloproteases (for example, MMP1, MMP2, MMP3,
MMP9, MMP12, and MMP13) and the precursor form of
uPA, pro-uPA [16]. These activated MMPs then can
degrade the diverse forms of collagens, kallikrein-related
peptidases, and other proteins in the ECM [18]. Thus, the
uPA-mediated conversion of plasminogen to plasmin cre-
ates a powerful proteolytic system capable of remodeling
the ECM and activating growth factors.
The second property of uPA that differentiates it from
most other proteases is that it functions while bound
with high affinity to a cell membrane receptor, known as
the uPA receptor or uPAR (also known as CD87) [19].
The structure of uPAR is dissimilar from that of type I
growth factor membrane receptors in lacking a trans-
membrane domain. Rather, uPAR is attached to the cell
membrane via a glycosylphosphatidylinositol link. As uPAR
lacks a transmembrane domain, it is unable to directlyinitiate downstream signaling. In order for such signaling
to occur, uPAR must interact with other molecules such as
epidermal growth factor receptor [20], platelet-derived
growth factor receptor [21], specific integrins [22], or
low-density lipoprotein receptor-related (LDLR) pro-
teins [23]. Signaling pathways activated following uPA
binding to uPAR include those involving the MAPK,
Jak-Stat, and focal adhesion kinase systems [24]. These
signaling systems regulate cell proliferation, migration,
and metastasis. uPA thus may trigger cell signaling by two
distinct mechanisms (that is, directly by binding to its
receptor uPAR and indirectly by activation of plasmin
which releases growth factors sequestered in the ECM)
(see above).
To restrain its proteolytic function, uPA catalytic activity
can be inhibited by two major endogenous inhibitors:
PAI-1 and PAI-2. Both PAI-1 and PAI-2 belong to the
serpin superfamily of protease inhibitors, PAI-1 being
designated serpinE1 and PAI-2 as serpinB2. Of these two
inhibitors, PAI-1 is the more rapidly acting, being 10- to
100-fold faster than PAI-2, at least in vitro [25]. Following
binding of PAI-1 to the uPA-uPAR complex, the trimole-
cular complex undergoes endocytosis [26]. Endocytosis
requires interaction with members of the LDLR family of
the endocytosis receptors, such as LRP, LRP2, and very-
low-density-lipoprotein receptor. After endoctytosis, the
complex is degraded, followed by partial recycling of the
free form of uPAR to the cell membrane [27].
Role of urokinase plasminogen activator and
plasminogen activator inhibitor-1 in cancer
Several studies using a variety of animal models have
shown that uPA is causally involved in promoting cancer
invasion and metastasis (for reviews, see [10,11]). Thus,
early reports showed that the administration of antibodies
to uPA, synthetic low-molecular-weight serine protease
inhibitors, or small interfering RNAs against uPA de-
creased cancer progression [10,11]. Further confirmation
of a role for uPA in metastasis was obtained with uPA or
plasminogen-deficient mice. Thus, Bugge and colleagues
[28] reported that a deficiency of plasminogen in the
mouse mammary tumor virus-Pym breast cancer model
reduced spontaneous metastasis without affecting tumor
growth. Using the same animal model, Almholt and
colleagues [29] found that a deficiency in uPA resulted in
the reduced formation of lung and lymph node metastasis.
As in the report by Bugge and colleagues, tumor growth
was not affected in this study.
As metastasis is a multistep event, it was important to
identify the specific step or steps in which uPA was
involved. Using the chick embryo system, Ossowski [30]
showed that uPA was involved in an early step in the
metastasis of Hep3 tumor cells. Similarly, using prostate
cancer cells, Bekes and colleagues [31] showed that uPA
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(that is, in the initial escape of tumor cells from the pri-
mary site). This escape of tumor cells was found to be
dependent on uPA-mediated plasmin activation and deg-
radation of the ECM protein fibronectin. In this model,
prevention of tumor escape was blocked by inhibition of
pro-uPA activation.
It might be expected that, based on its ability to inhibit
uPA activity, PAI-1 would suppress cancer progression.
However, consistent data from clinical studies (see below)
suggest that PAI-1 at levels found in tumor extracts is
involved in mediating cancer progression. Indeed, direct
evidence of a role for PAI-1 in cancer was recently
obtained when Masuda and colleagues [32] reported that
a specific inhibitor of PAI-1 blocked angiogenesis and
tumor progression in an animal model. The PAI-1 inhibi-
tor appeared to mediate its anti-tumor effects by interact-
ing with host PAI-1.
A possible mechanism by which PAI-1 promotes can-
cer progression is by enhancing angiogenesis. Evidence
of a role for PAI-1 in new blood vessel formation first
emerged when it was shown that PAI-1 deficiency in
mice resulted in defective angiogenesis [33-35]. In one
of these reports, PAI-1 was found to act by stimulating
migration of endothelial cells from perivascular areas
rich in the ECM protein vitronectin to sites rich in fibro-
nectin [35]. The mechanism by which PAI-1 promotes
angiogenesis may relate to its ability to protect the ECM
from excessive degradation, as this structure provides a
scaffold for endothelial cell migration and formation of
capillaries [34].
A further mechanism by which PAI-1 may enhance
cancer progression is by blocking apoptosis and thus
enhancing cell survival. PAI-1 was first reported to be
anti-apoptotic when Kwaan and colleagues [36] found
that the addition of recombinant PAI-1 to tumor cells
in vitro inhibited cytotoxic drug-induced apoptosis. Sub-
sequently, PAI-1 was shown to protect endothelial cells
[37] as well as several different types of tumor cells from
apoptosis. This blockage of apoptosis was found to be
dependent on uPA-mediated activation of plasmin and the
interaction of FasL with Fas [37].
Urokinase plasminogen activator and
plasminogen activator inhibitor-1 as biomarkers
in breast cancer
Analytical validation of urokinase plasminogen activator
and plasminogen activator inhibitor-1 assays
As mentioned at the start of this article, an essential
requirement for clinical use of a biomarker is analytical
validation of the assay to be used for its measurement.
Analytical validation ensures that an assay is reprodu-
cible and stable and has adequate sensitivity for detect-
ing the biomarker of interest in the fluid to be used forits measurement [38,39]. In addition, to ensure reprodu-
cibility between different laboratories, it is important
that clinically used assays be evaluated in external quality
assessment (EQA) programs [38].
Several different methodologies, including enzyme-
linked immunosorbent assay (ELISA) and immunohisto-
chemistry at the protein level and RT-PCR at the mRNA
level, have been used to measure uPA and PAI-1 in
research laboratories. Of these methodologies, the only
method subjected to analytical validation is ELISA [40,41].
In an early analytical study, Benraad and colleagues [40]
evaluated six different ELISAs for uPA measurement.
Although these different assays were developed independ-
ently and used different antibodies and standards, good
correlations were found between the different systems.
The absolute levels of uPA detected, however, varied
between the different assays. Importantly, all methods
gave acceptable within-assay precision [40,41]. Thus, using
quality control samples, the between-assay coefficient of
variation (CV) varied between 5.0% and 9.8% for uPA and
between 5.4% and 5.8% for PAI-1 [41]. Furthermore, all of
the assays were adequately sensitive to detect uPA levels
in extracts of breast cancer [40]. One of these assays -
Femtelle uPA/PAI-1 (Sekisui Diagnostics LLC, formerly
American Diagnostic Inc., Lexington, MA, USA) - was
later evaluated in an EQA program. In this multicenter
study, which involved six laboratories in Germany, the
between-laboratory CV varied between 6.2% and 8.2% for
uPA and between 13.2% and 16.6% for PAI-1 [41]. More
recently, in a randomized trial, CVs of 12% in an EQA
program were reported for both uPA and PAI-1 [42].
These CVs obtained with manual ELISAs would be
regarded as acceptable for clinical use.
Clinical validation
Clinical validation ensures that a positive biomarker test
result is associated with a particular disease or clinical
endpoint [43]. Appropriate endpoints for relating uPA
and PAI-1 include disease-free interval, overall survival,
or response to therapy. Given their involvement in
cancer progression, uPA and PAI-1 were logical candi-
dates for evaluation as potential prognostic biomarkers
in patients with cancer [44]. In a preliminary finding,
Duffy and colleagues [45] first reported that breast can-
cer patients with high tumor levels of uPA catalytic
activity had a significantly shorter disease-free interval
than patients with low activity levels.
These preliminary findings were soon confirmed when
Jänicke and colleagues [46,47], using an immunoassay,
reported that high uPA levels were associated with adverse
outcome in patients with breast cancer. Jänicke and col-
leagues [48] later found that, in addition to uPA, elevated
levels of PAI-1 predicted poor outcome as well. Subse-
quently, more than 20 independent groups confirmed
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that uPA and PAI-1 were statistically independent prog-
nostic biomarkers for patients with breast cancer and
importantly were prognostic in the subset of patients
with lymph node-negative disease [47,52,56,60,61,63,67,68].
The consistency of these findings across multiple patient
populations clearly demonstrates that both uPA and PAI-1
are related to outcome in women with breast cancer, in-
cluding the subgroup with lymph node-negative disease.
In addition to having a prognostic impact in breast
cancer, uPA and PAI-1 measurements in breast cancer
appear to possess therapy predictive value, especially in
predicting benefit from cyclophosphamide-methotrexate-
5-fluorouracil (CMF) in the adjuvant setting. In an early
prospective study (n = 761), Harbeck and colleagues [72]
reported that, although uPA and PAI-1 were associated
with outcome in patients who did not receive systematic
adjuvant therapy, this prognostic effect was lost in patients
who received adjuvant chemotherapy. Further evidence of
a chemotherapy predictive potential for uPA/PAI-1 was
obtained by using data from two separate sites (n = 3,424),
which showed that breast cancer patients with high levels
of the biomarkers derived an enhanced benefit from adju-
vant chemotherapy (mostly CMF) than those with low
levels [79]. In addition to showing a benefit from adjuvant
CMF, high levels of uPA and PAI-1 have been associated
with response to adjuvant anthracycline-based therapy
[81]. Further evidence of a predictive impact for uPA and
PAI-1 was the finding that detection of the uPA/PAI-1
complex was also associated with benefit from adjuvant
chemotherapy [80].
Demonstration of clinical utility
Although the above findings, when taken together, pro-
vide strong evidence that uPA and PAI-1 were independ-
ent prognostic biomarkers in breast cancer, they were
insufficient for these biomarkers to be recommended for
routine clinical use. In order for emerging biomarkers to
progress to the clinic, it is now widely accepted that, in
addition to analytical and clinical validation, demonstra-
tion of clinical utility in a level-of-evidence (LOE-1)
study is necessary. LOE-1 studies include validation in a
randomized prospective trial in which the biomarker
evaluation rather than an investigational drug is the
primary purpose of the trial, retrospective employment of
archival specimens from a previously conducted prospect-
ive trial, or a meta-analysis/pooled analysis of retrospect-
ive and prospective studies [5,6].
Uniquely for cancer prognostic biomarkers, uPA and
PAI-1 have undergone validation in two separate LOE-1
studies; that is, both have been validated in a prospective
randomized controlled trial (NCT1317108) and in a pooled
analysis of individualized patient characteristics. Valid-
ation in the prospective randomized trial involved multiplecenters in Germany [7,8]. In this trial (dubbed the Chemo-
N0 trial), uPA and PAI-1 were measured by ELISA
(Femtelle) in 556 patients with newly diagnosed axillary
node-negative breast cancer. To ensure accuracy and
precision for the uPA and PAI-1 assays, participation in
EQA for all participating centers was mandatory.
Pre-validated optimized cutoff points were used, and
patients with low concentrations of uPA (less than 3 ng/
mg of protein) and PAI-1 (less than 14 ng/mg of protein)
were subjected to surveillance without receiving adjuvant
systemic therapy. On the other hand, women with high
concentrations of uPA (at least 3 ng/mg of protein) or
PAI-1 (at least 14 ng/mg of protein) or both were ran-
domly allocated to adjuvant chemotherapy (CMF) or to
surveillance without systemic therapy. Patients refusing to
be randomly assigned underwent observation.
At the first interim analysis after a median follow-up
period of 32 months, patients with low concentrations
of uPA and PAI-1 had a significantly lower 3-year recur-
rence rate (that is, 6.7%) than those with high concentra-
tions of uPA or PAI-1 or both (that is, 14.7%) (P = 0.006)
[7]. These interim findings were recently confirmed
following the 10-year analysis of this trial (median
follow-up of 113 months) [8]. With this extended follow-
up period, the disease recurrence rates in the absence of
any adjuvant therapy (chemotherapy or endocrine ther-
apy) were 12.9% for patients with low concentrations of
uPA/PAI-1 and 23% for women in the high-uPA/PAI-1
group (P = 0.011). Considering these findings, the authors
concluded that measurement of uPA and PAI-1 could
identify almost half of the patients with lymph node-
negative breast cancer as being at low risk for recurrence
and thus being able to avoid the toxicity and costs of adju-
vant chemotherapy.
The second LOE-1 study to have validated the prog-
nostic utility of uPA and PAI-1 in breast cancer involved
a pooled analysis of individual patient demographics
data from 18 European datasets (n = 8,377) and was per-
formed by the European Organization for Research and
Treatment of Cancer (EORTC) Receptor and Biomarker
group [9]. All centers used immunoassay to measure
uPA and PAI-1 and were involved in ongoing quality
assurance programs for these biomarkers. Baseline
established clinical and histological factors in the multi-
variate analysis included tumor stage, tumor grade,
number of lymph nodes involved, hormone receptor sta-
tus, and patient age. Rather than using data exclusively
from published studies which may result in the introduc-
tion of bias (as positive studies are more likely to be
accepted for publication than negative findings), the
study included both published (n = 11) and unpublished
(n = 7) studies in the pooled analysis. Pooling of the data
followed by multivariate analysis showed that for both
lymph node-positive and lymph node-negative patients,
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pendently associated with poor outcome. Importantly,
both biomarkers were also prognostic in untreated (that
is, without systemic therapy) lymph node-negative pa-
tients, indicating that these proteins were pure prognostic
factors for this subgroup of patients. It should be stated
that this is one of the very few studies to have investigated
prognostic biomarkers in patients who did not receive
adjuvant systemic treatment.
As with their prognostic impact, the therapy predictive
value of uPA/PAI-1 has been confirmed in the above
two LOE-1 studies. Thus, in the first interim analysis of
the Chemo-N0 trial, high-risk lymph node-negative pa-
tients who had elevated concentrations of uPA or PAI-1
(or both) and who received chemotherapy exhibited a
significantly lower probability of disease recurrence than
those who had high concentration and who were sub-
jected to surveillance alone (for the per-protocol analysis,
relative risk (RR) = 0.27, P = 0.016; for the intention-to-
treat analysis, RR = 0.56, P = not significant) [7]. This lack
of significance in the intention-to-treat group may have
resulted because some patients did not adhere to the trial
protocol.
Confirmation of the above finding was obtained in the
10-year follow-up analysis [8]. With this longer follow-up
period, high-risk patients randomly assigned to chemo-
therapy also exhibited a significantly lower probability of
disease recurrence than those randomly assigned for ob-
servation only (in the per-protocol analysis, hazard ratio
(HR) = 0.48, P = 0.019; in the intention-to-treat analysis,
HR = 0.74, P = not significant). Confirmation of the che-
motherapy predictive role for uPA and PAI-1 was found
by using the pooled analysis of 18 datasets, referred to
above [82].
Measurement of urokinase plasminogen activator
and plasminogen activator inhibitor-1 are
cost-effective tests
Increasingly, in recent years, many governments and
insurance companies are requiring economic analyses of
the cost-effectiveness of new therapies and new tests
prior to approval for clinical use. An economic analysis
thus is becoming an additional hurdle (that is, in addition
to analytical validation, clinical validation, and demonstra-
tion of clinical utility) before measurement of a new bio-
marker can be approved for funding. From the above data,
it is clear that an upfront knowledge of the uPA/PAI-1
levels has the potential to reduce the use of unnecessary
adjuvant chemotherapy in a subset of patients with lymph
node-negative breast cancer.
Direct evidence that uPA/PAI-1 measurement is cost-
effective and indeed cost-saving was recently shown in a
prospective multicenter study involving 93 lymph node-
negative and ER-positive breast cancer patients [83]. Inthis economic analysis, measurement of uPA/PAI-1 was
found to decrease the use of adjuvant chemotherapy in
35 (37.6%) of the 93 patients investigated. Overall, meas-
urement of the two biomarkers led to a total cost saving
of €255,534. Considering the biomarker measurement
cost of €288 per sample, the authors calculated that
uPA/PAI-1 testing was cost-effective with a return on
investment ratio of 8.4:1 [83].
Current status of urokinase plasminogen activator and
plasminogen activator inhibitor as prognostic and
predictive biomarkers
To the best of our knowledge, uPA and PAI-1 are the
first breast cancer biomarkers to have their prognostic
and predictive utility validated in either a randomized
prospective trial or a pooled analysis of individualized
data from both published and unpublished data (that is,
in two independent LOE-1 studies) [5,6]. In recent years,
several multigene profiles have been proposed for deter-
mining prognosis in breast cancer [84] and indeed some
of these - for example, Oncotype Dx (Genomic Health,
Redwood City, CA, USA) and MammaPrint (Agendia,
Irvine, CA, USA) - are currently in clinical use. How-
ever, at this stage, none of the gene signatures has been
validated for clinical utility in LOE-1 studies, although
such trials are ongoing for Oncotype Dx (NCT00310180
and NCT01272037) and MammaPrint (NCT00433589).
It is of interest that preliminary results from a subset of
patients (n = 314) participating in the WSG Plan B trial
showed good agreement between uPA/PAI-1 and Onco-
type Dx in high-risk patients but less agreement in those
at low or intermediate risk of recurrence [85].
Because of their comprehensive validation, measure-
ment of uPA and PAI-1 in breast cancer is now recom-
mended by several expert panels in the US and Europe.
Expert panels recommending clinical use of the assays
include the American Society of Clinical Oncology [86],
the National Academy of Clinical Biochemistry (US)
[87], the European Group on Tumor Markers [88], the
European Society of Medical Oncology [89], and the
German Gynecological Oncology Group/Arbeitsgemein-
schaft Gynäkologische Onkologie [90] (Table 1).
Although the assays for uPA and PAI-1 have been
technically and clinically validated, these biomarkers are
still infrequently used for clinical purposes. One of the
reasons for this is that the original assays used for de-
tecting these proteins required relatively large amounts
of tumor tissue, limiting their application to patients
with small cancers. Recently, however, Thomssen and
colleagues [91] reported a strong and significant relation-
ship between uPA and PAI-1 protein concentration in
needle biopsy tumor tissue and level in the corre-
sponding larger tumor samples (for uPA, r = 0.789; for
PAI-1, r = 0.907; P <001 for both). Results from the needle
Table 1 Expert panels that include uPA and PAI-1 measurements in their guidelines
Panel Recommendation/Statement Reference
ASCO uPA/PAI-1 measured by ELISAs may be used for the determination of prognosis in patients with newly diagnosed, node-negative
breast cancer. Low levels of both markers are associated with a sufficiently low risk of disease recurrence, especially in steroid
hormone receptor-positive women who will receive adjuvant endocrine therapy and who will receive only minimal additional
benefit from chemotherapy. Furthermore, CMF-based adjuvant chemotherapy, compared with observation alone, provides
substantial benefit in patients with a high risk of disease recurrence as determined by high levels of uPA and PAI-1.
[86]
NACB Testing for uPA and PAI-1 may be carried out to identify lymph node-negative patients who do not need or are unlikely to
benefit from adjuvant chemotherapy. Measurement of both proteins should be performed because the information provided
by the combination is superior to that from either alone. Lymph node-negative patients with low levels of both uPA and PAI-1
have a low risk of disease recurrence and thus may be spared from the toxic side effects and costs of adjuvant chemotherapy.
Lymph node-negative women with high levels of either uPA or PAI-1 should be treated with adjuvant chemotherapy.
[87]
EGTM Recommends uPA and PAI-1 for determining prognosis in breast cancer, especially in the group of patients with lymph
node-negative disease. Validated ELISAs (that is, validated for both analytical and clinical performance) should be used for
determining these proteins.
[88]
ESMO uPA-PAI-1, a marker of tumor invasiveness, has been validated in prospective clinical trials as a prognostic marker for both
node-negative and node-positive breast cancer and can be used in treatment decision making for early breast cancer.
[89]
AGO Recommends uPA and PAI-1 for determining prognosis in breast cancer, especially in the group of patients with lymph
node-negative disease. It also acknowledges the predictive impact of the test.
[90]
AGO, Arbeitsgemeinschaft Gynäkologische Onkologie (German Gynecological Society); ASCO, American Society of Clinical Oncology; CMF, cyclophosphamide-
methotrexate-5-fluorouracil; EGTM, European Group on Tumor Markers; ELISA, enzyme-linked immunosorbent assay; ESMO, European Society of Clinical Oncology;
NACB, National Academy of Clinical Biochemistry (US); PAI-1, plasminogen activator inhibitor-1; uPA, urokinase plasminogen activator.
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a negative predictive value of 1.00 when compared with
findings from the corresponding larger specimens. This
report shows the feasibility of using a commercially avail-
able ELISA to quantitate uPA and PAI-1 levels in needle
biopsies of breast cancer tissue.
A further reason for the limited clinical use of uPA/
PAI-1 is that their measurement requires fresh or freshly
frozen tumor tissue. Currently, however, attempts are
ongoing to develop immunohistochemistry assays on
formalin-fixed and paraffin-embedded tissues for pre-
dicting patient outcome. Indeed, a recent report showed
that uPA and PAI-1 levels as measured by immunohis-
tochemistry on formalin-fixed and paraffin-embedded
tissue correlated significantly with values from a validated
ELISA [92]. However, it remains to be shown whether
immunohistochemically determined uPA and PAI-1 levels
on fixed tissue predict patient outcome as accurately as
values measured with ELISA.
Ongoing clinical breast cancer trials using
urokinase plasminogen activator and
plasminogen activator inhibitor-1
Currently, two randomized prospective trials are investi-
gating the predictive utility of uPA/PAI-1 for newer
forms of breast cancer systemic therapies. One of these,
which is known as the NNBC-3 trial and which has
enrolled 4,147 patients, is comparing fluorouracil (5-FU),
epirubicin, and cyclophosphamide followed by docetaxel
(3xFEC-3xDoc; FEC-D) with 5-FU, epirubicin, and cyclo-
phosphamide (6xFE100C; FEC) as adjuvant chemotherapy
for high-risk lymph node-negative patients (NCT01222052)
[93,94]. In this trial, unlike in the Chemo-N0 trial men-
tioned above, steroid hormone receptor-positive patientsmay receive endocrine therapy. Risk of disease recurrence
was determined by clinicopathological criteria [95] or
by a combination of uPA/PAI-1 and clinicopathological
criteria. In this trial, as in the Chemo-N0 trial, uPA and
PAI-1 levels were measured by the Femtelle ELISA and
all participating laboratories undertook EQA. The first
results are expected soon.
Another randomized trial involving measurement of
uPA and PAI-1 (WSG Plan B trial) has completed re-
cruitment with 2,448 high-risk node-negative and
node-positive patients [42,96]. The aim of this trial is
to compare an anthracycline- and taxane-based adjuvant
chemotherapy combination with an anthracycline-free
taxane-based regimen in patients with HER-2-negative
breast cancer (NCT01049425). As part of this trial, the
prognostic and predictive potential of uPA/PAI-1 will be
compared with that of Oncotype DX.
Urokinase plasminogen activator as a target for
anticancer treatment
In addition to appropriate validation and demonstration
of clinical utility, a desirable property of a cancer bio-
marker molecule is its capacity to function as a thera-
peutic target. Extensive data from animal models suggest
that uPA may indeed be a target for the treatment of
cancer [10,11,15]. Two main approaches have been used
to block uPA: inhibition of its catalytic activity by select-
ive low-molecular-weight inhibitors and prevention of
uPA from binding to uPAR by using antagonistic pep-
tides or antibodies (for detailed reviews, see [10,11,15]).
Although both of these approaches show promising effi-
cacy in animal models [10,11,15], low-molecular-weight
catalytic inhibitors have been the more investigated ap-
proach in clinical trials.
Note: This article is part of a series on Recent advances in
breast cancer treatment, edited by Jenny Chang. Other articles
in this series can be found at http://breast-cancer-research.
com/series/treatment.
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serine proteases have undergone evaluation in clinical
trials: WX-UK1 and WX-671 (also known as Mesupron or
upamostat) (Wilex, München, Germany). Whereas WX-
UK1 has to be administered intravenously, upamostat,
which is a pro-drug of WX-UK1, can be given orally. After
administration, upamostat is rapidly metabolized to the
active drug, WX-UK1. In phase I trials, these two inhibi-
tors were found to be well tolerated, and no serious side
effects were reported [11,97].
Since upamostat has the advantage that it can be
administered orally, it has been further investigated in
phase II clinical trials. In one of these trials involving
132 patients with first-line metastatic breast cancer, the
combination of upamostat and capecitabine was compared
with capecitabine alone (NCT00615940) [98]. Administra-
tion of upamostat and capecitabine resulted in median
progression-free survival (PFS) values of 8.3 months (95%
confidence interval (CI) 5.6 to 9.6) in the total study popu-
lation and 7.5 months (95% CI 4.2 to 12.8) in the control
group given only capecitabine. However, in the group of
patients who had received prior adjuvant chemotherapy,
PFS increased from 4.3 months (95% CI 2.6 to 9.7) in those
treated with capecitabine alone to 8.3 months (95% CI 5.6
to 10.9) in the group receiving upamostat and capecitabine.
In addition, overall response rate was higher in the group
receiving the combination therapy compared with those
receiving capecitabine alone (20% versus 12% at week 24).
Importantly, the combination of upamostat and cape-
citabine was reported to be safe and well tolerated, with no
unexpected toxicities other than those attributable to
capecitabine.
Upamostat has also been investigated in a randomized
phase II trial in patients with locally advanced pancreatic
cancer [99]. In this trial, 93 patients were randomly
assigned to receive gemcitabine either alone or in com-
bination with a daily dose of 200 or 400 mg upamostat.
Of the three groups, the combination of the higher dose
of upamostat and gemcitabine appeared to be most
efficacious with regard to improving patient survival.
Overall, upamostat was again well tolerated, the most
common side effects being asthenia, fever, and nausea.
It is unfortunate that neither of the above trials included
prior measurements of tumor uPA levels. Were tumor
uPA levels measured upfront and only those patients with
high levels treated, it is likely that response rates would be
higher. We recommend that, where possible, further trials
with anti-uPA treatments involve prior measurement of
uPA protein expression levels.
Conclusions
The data presented above, especially the results from the
Chemo-N0 randomized prospective trial [7,9], clearly
show that lymph node-negative breast cancer patients asidentified with uPA/PAI-1 measurements have an excel-
lent outcome, despite not receiving adjuvant chemother-
apy. Indeed, after 10 years of follow-up, only 10% of
these patients have died and 13% had developed a recur-
rence/metastasis [9]. As previously pointed out [9], had
these patients received hormone therapy, their 10-year
overall survival likely would have exceeded 90%. Com-
bined with its ability to identify lymph node-negative
breast cancer patients who can be spared adjuvant
chemotherapy (that is, women with low levels of uPA/
PAI-1), high concentration of these biomarkers can se-
lect women who are likely to benefit from such therapy.
Clearly, therefore, measurement of uPA and PAI-1 can
help toward personalizing treatment for women diag-
nosed with lymph node-negative breast cancer.
For clinicians managing breast cancer patients, the key
question is which of the available multigene/multipro-
tein tests is best. At present, the answer to this question
is unclear. In the absence of a clear answer, the following
might be considered in clinical decision making. Of the
available multi-parameter tests, the best validated is uPA/
PAI-1 [7-9]. Indeed, a commercial assay for measuring
both uPA and PAI-1 is now available (that is, Femtelle,
American Diagnostic Inc./Sekisui Diagnostics). Further-
more, this assay has received the CE mark for use in
Europe. The test is widely used in Germany and to a lesser
extent in France. The main reason for the limited use is
that the Femtelle assay requires fresh/freshly frozen tumor
tissue. Other multi-parameter tests such as Oncotype DX
and MammaPrint can be performed on formalin-fixed,
paraffin-embedded tissue and thus can offer more con-
venient assays. Hopefully, in the future, the various
multi-parameter tests can be compared for their prog-
nostic and predictive benefits as well as their cost-
effectiveness.Abbreviations
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